Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 2/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.30 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18218906 | 0.89 | PLA2G10 (0.33) | PLA2G10PLA2G5 | |
| SCHEMBL18221144 | 0.85 | PLA2G10 (0.30) | PLA2G10PLA2G5 | |
| SCHEMBL18206425 | 0.84 | NOTUM (0.33) | PSMB8PSMB5 | |
| SCHEMBL18915827 | 0.83 | PSMB8 (0.32) | PSMB8PSMB5PLA2G10PLA2G5 | |
| SCHEMBL18206665 | 0.83 | PSMB8 (0.33) | PSMB8PSMB5 | |
| SCHEMBL18206453 | 0.83 | PSMB8 (0.33) | PSMB8PSMB5 | |
| SCHEMBL18206454 | 0.83 | PSMB8 (0.33) | PSMB8PSMB5 | |
| SCHEMBL8740492 | 0.82 | STING1 (0.34) | PSMB8PSMB5PLA2G10PLA2G5 | |
| SCHEMBL18916542 | 0.82 | MEN1 (0.38) | PSMB8PSMB5 | |
| SCHEMBL18219020 | 0.82 | PSMB8 (0.31) | PSMB8PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170157116-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2017-06-08 | — | — | US | disclosed |
| US-20170151232-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2017-06-01 | — | — | US | disclosed |
| US-20160326182-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326182-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | OPRM1, OPRK1, OPRD1 | PSMB8 1705/4885PSMB5 1225/4885PLA2G10 3044/4885 |
| US-20170157116-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | OPRM1, OPRK1, OPRD1 | PSMB8 1705/4885PSMB5 1225/4885PLA2G10 3044/4885 |
| US-20170151232-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | OPRM1, OPRK1, OPRD1 | PSMB8 1705/4885PSMB5 1225/4885PLA2G10 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.